Get started
Replimune Group, Inc.Replimune Group, Inc.Replimune Group, Inc.

Replimune Group, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Options

REPL chart


Full chart

REPL upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪578.38 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−3.14 USD
Net income (FY)
‪−215.79 M‬ USD
Revenue (FY)
0.00 USD
Shares float
‪61.80 M‬
Beta (1Y)
2.03

Employees


Employees (FY)
331
Change (1Y)
+47 +16.55%
Revenue / Employee (1Y)
0.00 USD
Net income / Employee (1Y)
‪−651.95 K‬ USD

About Replimune Group, Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
Sushil Patel
Website
replimune.com
Headquarters
Woburn
Founded
2015
FIGI
BBG00L8Z22R1
Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

REPL news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Check out other big names from the same industry as REPL.

Frequently Asked Questions


The current price of REPL is 7.71 USD — it has increased by 2.66% in the past 24 hours. Watch Replimune Group, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Replimune Group, Inc. stocks are traded under the ticker REPL.
REPL stock has fallen by −1.03% compared to the previous week, the month change is a −35.43% fall, over the last year Replimune Group, Inc. has showed a 9.99% increase.
We've gathered analysts' opinions on Replimune Group, Inc. future price: according to them, REPL price has a max estimate of 31.00 USD and a min estimate of 17.00 USD. Watch REPL chart and read a more detailed Replimune Group, Inc. stock forecast: see what analysts think of Replimune Group, Inc. and suggest that you do with its stocks.
REPL reached its all-time high on Nov 19, 2020 with the price of 54.85 USD, and its all-time low was 4.92 USD and was reached on May 29, 2024. View more price dynamics on REPL chart.
See other stocks reaching their highest and lowest prices.
REPL stock is 1.77% volatile and has beta coefficient of 2.03. Track Replimune Group, Inc. stock price on the chart and check out the list of the most volatile stocks — is Replimune Group, Inc. there?
Today Replimune Group, Inc. has the market capitalization of ‪593.78 M‬, it has decreased by −7.35% over the last week.
Yes, you can track Replimune Group, Inc. financials in yearly and quarterly reports right on TradingView.
Replimune Group, Inc. is going to release the next earnings report on May 15, 2025. Keep track of upcoming events with our Earnings Calendar.
REPL earnings for the last quarter are −0.79 USD per share, whereas the estimation was −0.71 USD resulting in a −11.88% surprise. The estimated earnings for the next quarter are −0.75 USD per share. See more details about Replimune Group, Inc. earnings.
Replimune Group, Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
REPL net income for the last quarter is ‪−66.34 M‬ USD, while the quarter before that showed ‪−53.05 M‬ USD of net income which accounts for −25.04% change. Track more Replimune Group, Inc. financial stats to get the full picture.
No, REPL doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Apr 16, 2025, the company has 331 employees. See our rating of the largest employees — is Replimune Group, Inc. on this list?
Like other stocks, REPL shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Replimune Group, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Replimune Group, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Replimune Group, Inc. stock shows the sell signal. See more of Replimune Group, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.